Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Ratifies Free Trade Agreement With U.S., Pleasing Pharma Industry

This article was originally published in PharmAsia News

Executive Summary

Patent linkage provisions among key benefits for the pharmaceutical industry.

You may also be interested in...

Korean And U.S. Presidents Welcome Long-Awaited Korea-U.S. FTA Ratification; Now Eyes on Seoul

SEOUL -Korean President Lee Myung-bak and U.S. President Barack Obama both welcomed and celebrated the U.S. Congress's ratification of the Free Trade Agreement, saying the historic free trade deal will benefit both countries. But ratification is still needed in South Korea, and political maneuvering by the country's ruling and opposition parties may delay the process

Pharma Industry Applauds Final Push For Ratification Of Korea-U.S. FTA, Patent Linkage, Transparency, Among Benefits

SEOUL - South Korean Prime Minister Kim Hwang-sik called on cabinet ministers to ratify Korea's free trade agreement with the United States during the country's National Assembly session Oct. 4

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts